The Star Online [2 March 2018]
“Hope for hepatitis C patients”
La Prospérité [1 February 2018]
“Ministère de la Santé : Oly Ilunga organise une matinée scientifique sur la trypanosomiase” – “Ministry of Health: Oly Ilunga organizes a scientific morning on trypanosomiasis”
Le Figaro [1 February 2018]
“Sanofi: 1ère étape pour autoriser un traitement” – “Sanofi: 1st step in authorizing a treatment”
Pharmazeutische Zeitung [1 February 2018]
“Mit 70er-Jahre-Revival gegen die Schlafkrankheit” – “70s revival to fight sleeping sickness”
PharmaTimes [1 February 2018]
“Sanofi, DNDi seek EMA review for sleeping sickness drug”
Reuters [31 January 2018]
“Sanofi and partner seek European Medicines Agency review for sleep sickness product”
Medicalfacts [31 January 2018]
“Congo maakt werk van eliminatie slaapziekte” – “Congo is working on elimination of sleeping sickness”
27 January 2018
Medicines for Malaria Venture and DNDi delivered a joint statement at WHO’s Executive Board 142, urging WHO to recognize the urgent need for research and development, access, and uptake of child-friendly medicines.
1-2 March 2018
Kuala Lumpur, Malaysia
Jean Michel Piedagenel, Head of DNDi South East Asia Regional Office, Malaysia – panel discussion on access to hepatitis treatment
François Simon, Clinial Trial Leader Paediatric HIV/HCV, DNDi, Switzerland – expert talk on clinical trials
by Marchiol A, Forsyth C, Bernal O, Valencia C, Cucunubá Z, Pachón E, Soto M, Batista C.
Pan American Journal of Public Health, December 2017
El País [19 December, 2017]
“Ocho millones de personas olvidadas” – “Eight million people forgotten”
Le Figaro [14 December, 2017]
“Un traitement contre la maladie du sommeil” – “A treatment for sleeping sickness”
Le Monde [27 November, 2017]
“En Afrique, environ la moitié des séropositifs sont sous traitement” – “In Africa, about half of HIV-positive individuals are treated”
Scroll.in [27 November, 2017]
“India will miss its deadline to eliminate kala azar by the end of December”
Tribune de Genève [26 November, 2017]
“Nouvelle thérapie pour malades oubliés” – “New treatment for neglected patients”
December 8, 2017
DNDi presented at the event on the NTD Drug Discovery Booster, Chagas disease, and mycetoma.
The journey to the sleeping sickness trial site in Isangi from the DNDi office in Kinshasa begins in the domestic airport of DRC’s capital city and ends more than a day later halfway across the country in a barge crossing the Congo river. In between: hours spent navigating potholed dirt roads, collapsed bridges, checkpoints, and multiple river crossings. Once at Isangi, canoes must be used to reach many of the patients as there are no roads.
Yet for DNDi’s clinical team in DRC, Isangi is one of the easier-to-reach sites. The DRC and the Central African Republic (CAR) both pose daunting challenges that must be overcome to develop better treatments for patients suffering from sleeping sickness.